Gilead's HIV Quad pill tops Atripla in neurological safety
This article was originally published in Scrip
Executive Summary
Updated data presented by Gilead Sciences on 7 March revealed that its experimental once-daily, fixed-dose, four-in-one HIV pill Quad not only was as effective as the company’s US FDA-approved drug Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate), but its safety was comparable, and in fact beat the triple-combo medicine in demonstrating fewer adverse neurological effects.